Search tips
Search criteria 


Logo of ajbrLink to Publisher's site
Am J Blood Res. 2012; 2(2): 86–97.
Published online 2012 April 22.
PMCID: PMC3384399

Advances and application of radioimmunotherapy in non-Hodgkin lymphoma


The activity of radio-immuno conjugate in Non-Hodgkin Lymphoma (NHL) has resulted in FDA approval of two antibodies, Y90 Ibritumomab tiuxetan and I131 tositumomab. Both these agents target CD20, a receptor widely expressed in B-Cell NHL. These immunoconjugates deliver their radioactive payload to the malignant clone in the bone marrow and lymph node. Their use has been associated with modest improvement in survival end points among several lymphoma histologies. The promising effect on disease control as well as their efficacy in disease relapse is encouraging in low grade lymphoma. Radioimmunotherapy (RIT) is increasingly being explored in the setting of consolidation as well as conditioning regimens prior to stem cell transplantation. Here, we summarize the clinical use, complications and future applications of RIT in NHL.

Keywords: Radioimmunotherapy, non-Hodgkin lymphoma, stem cell transplantation, CD20 target


Non-Hodgkin lymphoma (NHL) is a group of heterogeneous histologies, with variable clinical outcomes [1]. Chemotherapy, immunotherapy and radiation therapy have been the main modalities of treatment in this disease. With the advent of monoclonal antibodies, especially the CD20 directed rituximab in combination with multi agent chemotherapy, high rates of initial response can be achieved. Fewer patients however, attain a cure and many eventually relapse with disease that is often less sensitive to chemotherapy. Pre-clinical data supports that along with development of rituximab resistance, chemotherapy resistance emerges [2]. The effectiveness of Immunotherapy alone in the setting of relapse suggests an intact target and host immune function [3].

The ability to deliver radioactivity directly to the tumor via an antigenic target was the rationale for developing Radioimmunotherapy (RIT). RIT in lymphoma acts as a means of reaching the target with its radioisotope payload, rather than invoking antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity [4,5]. The two chemo immunotherapy agents approved for use in NHL are yttrium Y90 Ibritumomab tiuxetan (Y90I, Zevalin) and I131 Tositumomab (I131T, Bexxar). The characteristics of the two antibodies are compared in Table 1.

Table 1
General Characteristics of Radioimmunotherapy antibodies

Mechanisms of action

While delivering RIT, the amount of radiation that reaches the target can be accurately determined. It is thus possible to administer higher doses of tumor site specific radiation. In addition, the amount of off target radiation to major organs is predictable and therefore measured for toxicities. The radioactive conjugates are concentrated on the cell surface because of the antigen density. Radioactive particles can deliver their effects over distances of 1-5mm.

The major mechanism of action of RIT is direct apoptosis. Pro apoptosis signals are up regulated including CD95 ligand and CD95 receptor both of which activate caspases which effect apoptosis through the extrinsic pathway [6]. Furthermore, mitochondrial damage caused by radiation leads to release of cytochrome c which in turn leads to apoptosis via the intrinsic pathway [6,7].

Clinical implication in NHL subtypes

Clinical trials evaluating the role of RIT in various histological subtypes of NHL are detailed in Table 2. Here we summarize the results of major clinical trials [8-17].

Table 2
Select Clinical Trials utilizing radio-immunotherapy in refractory Low Grade NHL

Clinical experience of RIT in Low grade Lymphoma

Follicular lymphoma (FL), a relatively indolent yet incurable disease, was the target for early development of RIT. The quest for safer mechanisms of therapy including targeted agents is an attractive strategy. The natural history of this disease is for more mutant and chemotherapy resistant clones to evolve as the disease is retreated with multi agent chemotherapy. In FL, where the malignant clone retains the expression of CD20, RIT is an additional option to be considered. Furthermore as described previously, proximity to the cell (assured through binding of the CD20 receptor) is critical for activity.

RIT in relapsed lymphoma

The encouraging results of several phase I/II trials led to conduct phase III trials.

In a randomized study of 143 patients with mainly FL histology, patients were treated with rituximab or Y90I with median number of 2 prior regimens [12]. The overall response rate (ORR) was statistically significant between the two groups 80% versus 53% with the most notable response of 86% in the FL group. Furthermore, patients who were randomized to receive RIT achieved a complete response (CR) of 30% versus 16% among patients receiving rituximab (p=0.04). The median duration of response was 14.2 months with 12.6 months to time to progression (TTP) in the Y90I group.

RIT has also shown efficacy in patients with no response to rituximab. A prospective phase II trial by Horning et al [14] explored the use of I131T in 40 patients of whom 60% had been rituximab non-responders. The ORR was 65% with 38% achieving CR. At 3 year follow-up the median progression free survival (PFS) was 10.4 months in all patients and 24.5 months in responders. Of note, follicular grade 1 or 2 patients with tumors ≤ 7 cm (n = 21), the ORR and CR rates were 86% and 57%. In this subgroup the estimated 3-year PFS was 48%. A study by Kaminski et al. [17] explored re-treatment of 32 patients with I131T who previously had a response of greater than 3 months. These patients showed an ORR 53% with 25% CR. Interestingly the median duration of response was similar with 13.6 months initially versus 15.2 months in the retreatment group. These patients experienced similar Grade 3-4 hematologic toxicities as compared with previous studies (neutropenia 50%, thrombocytopenia 43%).

In a phase 3 cross-over trial by Davis et al [16], 78 patients with relapsed refractory NHL were randomized to tositumomab alone (without radioactive conjugate) or I131T. Response rates were higher in the RIT arm (55% compared to 19% p =.002), CR 33% compared with 8% (p =.012) and the median duration of response was not yet reached in the I131T arm. In the cross-over group the CR rates were 42% versus 0% with OR of 68% versus 16% (p =.002) Toxicity pattern was similar as previous studies with grade 3-4 neutropenia seen among 33% in the RIT arm compared with 8% in the tositumomab alone arm. No thrombocytopenia was seen among those who had tositumomab as a single agent compared with 33% in the I131T arm.

RIT in newly diagnosed low grade lymphoma

The updated results of I131 T as initial monotherapy in 76 patients for previously untreated advanced stage FL were recently reported [17]. The 10 year overall survival was 82% and median PFS was 10.9 years in patients who attained CR. Notably in this trial PCR for Bcl-2 rearrangements were run on patients in CR and showed that 80% achieved a molecular response. While there was some hematologic toxicity, mainly Grade 3 neutropenia and thrombocytopenia, 34% and 17% respectively, no patients required growth factors or transfusion support. This data is convincing to support the use of RIT in a selected group of patients with newly diagnosed low grade NHL.

RIT as consolidation in FL

Among rituximab naïve patients, RIT used as consolidation therapy chemotherapy with CHOP, CVP or fludarabine based regimens, CR rates were notably improved. The FLUMIZ trial [18] studied the use of 90Y-ibritumomab tiuxetan following 6 cycles of Fludarabine and Mitoxantrone in 57 stage III/IV patients. Of the 14 patients who had PR after initial chemotherapy, 12 achieved CR (96.5%). The 3-year PFS and overall survival (OS) rate were 76% and 100% respectively. The Grade 3-4 hematologic toxicities were most notably 52% neutropenia and 63% thrombocytopenia with 23% receiving colony stimulating factors. A follow-up study by Zinzani et al [19] studied consolidation Y90I following 4 cycles of Fludarabine, Mitoxantrone, and Rituximab in a population of 55 patients with Stage III/IV disease. Following therapy there was a 100% ORR with 81% attaining CR. The 3 year PFS and OS were 81% and 100% respectively.

Jacobs and colleagues [20] studied R-CHOP therapy followed by Y90I and extended dosing rituximab in a population of FL patients with Stage III-IV disease. After RIT, the CR rate was noted to be 89% by PET. The 2 year ORR was 73%. Hainsworth et al observed the response of 41 patients following R-CHOP (88%) and CVP-R (12%) combined with Y90I 4 weeks later. The ORR and CR were measured at 95% and 72% respectively with 39% Grade 3-4 neutropenia and 36% Grade 3-4 thrombocytopenia. The OS and PFS at 5 years were documented to be 96% and 64% [21].

The international phase III study (FIT) evaluated the role of Y90I following initial response to chemotherapy. Patients who achieved a partial response (PR) following initial therapy appear to benefit the most with consolidation RIT. In this study only 14% of patients received rituximab with induction chemotherapy. Initially, Morschhauser et al [22] reported the results on 414 previously treated patients with FL were randomized to Y90I versus observation following chemotherapy. Y90I was effective with PFS 36.5 versus 13.3 months in the observation arm at a median follow up of 3.5 years. At an extended follow up of this study, the median PFS at 5.5 years was 49 months vs. 14 months. The median PFS was prolonged for all subgroups examined including those in PR, CR and all International Prognostic Index (IPI) groups. There was however no significant difference in OS among both the groups. The incidence of MDS/AML was 3% in the consolidation arm.

The results of the phase III intergroup study (S0016) presented by Press et al. evaluated the role of rituximab and CHOP therapy versus CHOP followed by I131T in patients in newly diagnosed FL with a primary end point of PFS. Of the 554 patients enrolled in this study, the 2-year estimate of OS was 97% in the CHOP-R arm and d 93% in the CHOP-RIT arm (p=0.08). There were no significant differences in the incidence of hematological toxicities or ORR [23].

In summary, RIT appears to play a significant role in upfront, consolidation or relapsed FL. The most benefit of such treatment is likely to be obtained when considered early on in the natural history of disease with the likelihood of targeting radiologically detectable disease among those achieving PR to induction therapy. The improvements seen in patients who have attained a CR, argues for its role in targeting minimal residual disease.

Intermediate grade lymphoma and RIT

The kinetics of RIT include a long half-life (64 hours for Y90 I and 193 hours for I131T) with relatively slower onset of action. These characteristics may limit its utility in the setting of an aggressive lymphoma with a rapid doubling time. Nonetheless, Y90I and I131T have been used as consolidation therapy in de-novo and transformed diffuse large B cell lymphoma (DLBCL). Often times, it has been used as an adjunct with high dose chemotherapy and stem cell rescue. Clinical trials in this histological subtype are limited to phase II studies. A summary of the trials in DLBCL or transformed lymphoma are detailed in Table 3 [24-29].

Table 3
Select clinical trials of radio-immunotherapy in intermediate grade NHL

A phase II trial by Yang and associates (24) studied the use of Y90I in Stage I/II DLBCL patients (n=21) with bulky disease. Patients were treated with six cycles of R-CHOP chemotherapy; patients with either PR or CR were then given Y90I. The ORR was noted to be 81%. After 28 months the 3 year PFS and OS were 75% and 85% respectively.

A further study examined the use of Y90I in elderly patients (n=104) who had either failed chemotherapy with or without rituximab or relapsed after achieving a CR [26]. Patients were stratified into 2 groups, one group that failed chemotherapy without rituximab (A) and one that failed therapy with rituximab (B). The non-rituximab group was further stratified into those who failed initial therapy (A1) and those who achieved complete response and relapsed (A2). In patients in group A1 the ORR was 67% with 24% experiencing progressive disease and 9% with stable disease. In group A2 there was a 100% ORR with 93% CR. Finally in group B, there was an OR of 65% with 38.5% CR; progressive disease was documented in 35% of patients. The median survival documented at median follow-up of 21.7 months was 21.4, 22.4, and 4.6 months respectively in Groups A1, A2, and B. The major hematologic toxicity was Grade 3-4 thrombocytopenia in 79% of patients with 2 deaths in study attributed to intracranial hemorrhage related to thrombocytopenia. A single arm study at the University of Michigan [27] examined the use of I131T for relapsed/refractory disease included 17 patients with either intermediate or high grade lymphoma. Forty-one percent of patients achieved a response; however none of these patients achieved CR. Intermediate grade histology was revealed in subgroup analysis to be a risk factor for shortened PFS (relative risk [RR] = 4.8, p <.0001).

A study by Wang et al [28] examined use of Y90I in patients with relapsed/refractory mantle cell lymphoma (MCL). Patients with Stage I-IV disease had failed an average of 3 prior chemotherapy regimens including 94% with prior Rituximab based therapy. Sixty-seven percent achieved some reduction in tumor bulk while there was a 15.5% CR. The OS was 21 months while the event free survival (EFS) was 6 months; notably patients who had achieved a CR/PR had a measurably increased EFS (21 months versus 3 months p<0.0001).

A study by Tsimberidou [29] et al examined the use of Y90I in Richter’s transformation from CLL. These patients had received a median of 5 therapies with one occurring after transformation. Of note, none of the patients had a response except for interval decrease in lymphadenopathy. Patient’s median time to progression was measured at only 41 days.

A multicenter, randomized study is evaluating the role of Y90I following R-CHOP therapy in patients with DLBCL (ZEAL study). Based on the listed studies, RIT appears to have a role as consolidation therapy as well as relapsed intermediate grade lymphomas.

RIT in stem cell transplant (SCT)

The perceived role of RIT in SCT was to deliver a myeloablative dose to the patient thereby eliminating residual NHL and marrow reconstitution by stem cell rescue. RIT is able to deliver radiation directly at the tumor site unlike Total Body Irradiation (TBI) which delivers same dose of radiation to all organs of the body at a significant cost in terms of side effects. Several studies were undertaken to evaluate the feasibility of adding RIT to chemo and whether that mechanism may be as effective with fewer side effects as compared with TBI. An additional advantage with I131T was that its bio-distribution, metabolism and half-life differed significantly among patients. These parameters can be reliably measured and exploited to provide patient specific (individualized) dosing to accentuate therapeutic effect against the cancer cell [30-38]. Pertinent trials involving RIT and stem cell transplant are listed on Table 4.

Table 4
clinical trials utilizing RIT in peri-transplant setting

A phase I/II study by Nademanee et al [31] studied the use of Y90I in conditioning for autologous stem cell transplant when combined with high-dose etoposide (VP-16) 40 to 60 mg/kg (day -4) and cyclophosphamide 100 mg/kg (day -2). Patients received dosimetry on day -21 followed one week later with Y90I. Day -7 bone marrow was conducted to estimate delivery of radiation; patients were redosed if total irradiation was deemed to be less than 5 cGy. The study group included 31 patients who had a median of 2 previous lines of therapy with histology notable for FL (n = 12), DLBCL (n = 14), and MCL (n = 5). Following stem cell infusion, the median time to neutrophil and platelet recovery were 10 and 12 days respectively. The major Grade 3-4 toxicities were most notably Infection 74% and mucositis 34%. The estimated two year OS and relapse free survival (RFS) were 92% (95% CI, 82%-100%), and 78% (95% CI, 61%-96%) respectively. The best survival was noted in patients with FL histology (100% 2 year OS/RFS).

A recent phase II study by Kang et al [32] studied the use of Y90I when combined with intravenous busulfan, cyclophosphamide, and etoposide (Bu/Cy/E) followed by auto-SCT in patients with relapsed/refractory B-cell lymphoma. The majority of patients in this population had DLBCL (n = 14), with FL and MCL (n = 2). The regimen involved giving rituximab 250 mg/m2 on day -21 with Y90I on day -14 at dose of 0.4 mCi/kg followed by busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5), Cyclophosphamide (IV, 50 mg/kg on days -3 and -2), and etoposide (IV, 200 mg/m2 every 12 h on days - 5 and -4). The major non-hematologic toxicities observed were Grade 3 diarrhea and nausea in 15.8% with no Grade 4 toxicities. At a median follow up of 29.4 months, 12 patients (63.2%) had relapsed with 8 deaths. The estimated 3- year OS and EFS rates were 52.6% and 26.3% respectively.

Krishnan et al [33] conducted a study of Y90I in combination with high dose chemotherapy and stem cell rescue using carmustine, cytarabine, etoposide and melphalan (BEAM). Eligible patients had CD20 positive refractory FL, poor risk MCL (requiring two or more regimens to achieve PR or CR), DLBCL (represented half of the population) or transformed DLBCL. Stem cells were collected and they were treated in the outpatient setting with the dose of Y90I capped at 40mCi. Y90I was administered on day -14 and the protocol for auto-SCT was initiated on day - 7. Disease status was evaluated at days 30, 100, 180 post-transplant. The two year OS was 87.9% (95% CI 68.8 - 96.9). Elderly patients benefited from treatment and therapy was safely administered in the outpatient setting.

Another study by Shimoni et al [34], evaluated the role of Y90I in conjunction with BEAM. These patients were similar to the previous with two year OS 67% (95% CI 46 - 87%) and PFS 52% (95% CI 31 - 72%). This study confirms that Y90I can be safely combined with conditioning regimen prior to SCT.

The response of elderly patients to conditioning with RIT was studied by Gopal et al. [39]. This study examined 24 patients with DLBCL (n = 9), MCL (n = 7) and FL (n = 8) with a median age of 64 who were treated with an I131T infusion only. Patients received dosimetric infusion on day -24 followed by therapeutic infusion on day -14 (median, 19.4 Gbq [525 mCi]; range, 12.1 to 42.7 Gbq [328 to 1,154 mCi]) to deliver 25 to 27 Gy. At a median follow-up of 29 months the OS and PFS were 59% (CI 95%, 37 - 80%) and 51% (CI 95%, 30 - 72%) respectively. Patients with DLBCL had inferior OS amongst the groups, whilst MCL had poor PFS.

Press et al conducted [36] a phase I/II study evaluating maximum tolerated dose (MTD) of I131T in combination with etoposide and cyclophosphamide among 55 patients. Patients were evaluated at months 1, 3, 6, and 12, and annually thereafter. All patients developed expected grade 4 neutropenia and the median duration of recovery (ANC > 500) was 10 days for peripheral blood and 13.5 days for bone marrow harvest. Platelet engraftment occurred at 13 days for peripheral blood and 23 days for patients who received bone marrow harvest. The maximum tolerated dose was achieved at dose level of 25Gy I131T, Etoposide 60 mg/kg and cyclophosphamide 100 mg/kg). Multivariate analysis showed that PFS and OS were superior in the I131T treated group; however it was difficult to interpret due to the histologic differences between groups.

Fewer studies established the role of RIT in the setting of allogeneic stem cell transplantation (allo-SCT). The study by Bethge et al [37] was designed to evaluate the feasibility of adding RIT to allo-SCT. The primary objective of this study was to evaluate the feasibility and assess treatment related toxicities. A recent study by Gopal et al [38] examined the use of RIT in conditioning for a non-myeloablative allo-SCT. As in previous studies, patients received dosimetry on day -21 prior to dosing on day -14 with 250 mg/m2 of rituximab before the therapy dose of 0.4 mCi/kg of Y90I, with a maximum dose of 32 mCi. Fludarabine 30 mg/m2 was delivered on day -7 to -5 with 2 Gy TBI on day 0. The treatment regimen revealed the expected myelosuppressive side effect profile with time to neutrophil > 500/μL was 17 days (range, 0-34 days) and platelets > 50 000/μL was 11 days (range, 0-147 days). At median follow-up of 1.7 years, the estimated 2 years OS and PFS were 54% (95% confidence interval [CI], 37%-68%) and 31% (95% CI, 16%- 48%), respectively. Notably, univariate analysis revealed that patients with indolent histologies had better OS and PFS when compared with aggressive histology (p <0.01).

The application of RIT in SCT offers the advantage of eradication of minimal residual disease and possibly even disease control until the effect of Graft versus lymphoma takes effect.

Current indications for approved use of RIT

The following are the FDA approved indications for the use of RIT

I131 T is approved for the treatment of relapsed or refractory CD20 positive, low-grade, follicular, or transformed NHL.

Y90 I is approved for the Treatment of relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL); treatment of follicular NHL in patients who achieve a response (partial or complete) to first-line chemotherapy.

Can RIT replace rituximab?

The recent intergroup trial (S0016) concludes that in patients receiving either CHOP-R or CHOP-RIT there are no significant differences in either arm and either arm is considered superior in patients with newly diagnosed follicular lymphoma. This is an important conclusion as patients who are unable to tolerate rituximab infusions should be considered for I131T at the end of chemotherapy. This is further supported by a meta-analysis of RIT as consolidation for untreated patients with FL. Consolidative RIT appears to benefit patients with untreated FL and compares favorably with rituximab given after chemotherapy [40]. It is however unclear if this approach is comparable in patients who received R-chemotherapy as induction followed by rituximab maintenance. Among patients being considered for rituximab monotherapy as retreatment for relapsed low grade lymphoma, there appears to be an effective role for RIT.

Based on these data, RIT may not replace rituximab; however is an alternate promising anti-lymphoma approach.

Criteria for application of RIT

Due to the known hematological toxicities of RIT, it is recommended that prior to consideration of either of the approved agents, the marrow cellularity be at least at 15% with <25% involvement by lymphoma clone. It is also recommended that patient have an absolute neutrophil count > 1.5x109/L and a platelet count of at least 150x109/L. In relapsed patients however, a reduced dose of RIT can be considered in patients with a platelet count between 100-150 x109/L. A reduced dose of Y90I was studied in 30 patients with relapsed FL who received 2 prior therapies and with mild thrombocytopenia defined as platelet count between 100,000 to 149,000 [13]. Patients were excluded if they had prior RIT, Rituximab, or extensive BM involvement >25%. Statistical analysis on the data included relation of dosimetry to hematologic toxicity which displayed no significant relation in 21 out of 24 analyses, however in the remaining 3 subsets there was a relation between dosimetry and platelet nadir. The rate of complete response was 37% with Grade 4 thrombocytopenia noted in 13% of patients.

Cytogenetic testing of bone marrow is recommended prior to therapy with RIT to identify chromosomal abnormalities that may preclude the use of RIT. Tumor size may play a role while considering RIT. In a study by Gokhale et al., Y90I when administered to patients with tumor size >5cm had a higher local relapse rate as compared with tumor size <5cm (83% vs. 28%) [41]. Historically, in the trials with RIT, bulky disease was not included in the studies.


The majority of the clinical trials with RIT have demonstrated similar pattern of toxicity.

Early complications

Patients who receive RIT can have infusional reactions similar to those seen with naked monoclonal antibodies. Grade 1-2 infusion reactions are mild and consist of urticaria or hives only without bronchospasm. In most instances, infusion may only need to be temporarily held or rate reduced and patients can be safely re-challenged with the same drug if needed and premedication is indicated. In the event of grade 3 infusion reaction that causes cardiovascular collapse, bronchospasm and hypotension the antibody will need to be discontinued and may not be re exposed to the antibody. With RIT, grade 3-4 infusion reactions are rare (less than or equal to 2%) and at least partially preventable with premedication with steroids and H2 blockers. The risk of immunogenicity was higher in patients with no prior therapy [16].

The most significant sub-acute complications occur within days to weeks and have to do with marrow suppression which is expected since the radionuclides localize to the marrow. Severe (grade 3-4) marrow suppression occurs on an average of 22 - 75% and duration of grade 4 was 10 - 14 days in the stem cell transplant patient. In general, marrow suppression, especially neutropenia can persist for some time especially in the non SCT setting where patients may not be on growth factors. Concerning tositumomab, thyroid exposure can cause hypothyroidism. This can be effectively blocked with strict adherence to thyroid shielding and potassium iodide administration during treatment. Hypothyroidism may occur months after exposure therefore thyroid hormone levels should be monitored on a routine basis in patients treated with this drug [42].

Late complications

Late complications can occur from months to years after the administration of RIT. Some studies have looked at the development of myelodysplastic syndrome (MDS) and cases have been described up to 2.5-3% [43,44]. It is a difficult task to tease apart the causal effect of RIT in patients who have already been exposed to other multi agent chemotherapy drugs including purine analogs, which are known to cause MDS. In the first-line indolent trial, where RIT was used as consolidation, the incidence of MDS/acute myeloid leukemia was 3% as compared with 1% in the control group [44].


RIT is an effective treatment strategy in NHL. Despite its effectiveness, it has been underutilized. This is likely due to the complexity of administration that makes it less attractive for its wide-spread use. We however, believe that RIT should be considered early on in relapsed patients with low grade lymphoma given its excellent response. It also appears to be promising as a consolidative strategy in intermediate grade lymphoma, though further studies need to be performed to definitively establish its role. It has also shown encouraging results when used as conditioning regimen in patients undergoing SCT. A potential role is to consider its use after an attenuated course of chemotherapy.

Future directions

With advances in genetic engineering, pretargeted RIT using fusion proteins is an area of progress [45]. As the currently approved RIT drugs find their way to expand their use, the future of RIT is bright. Several antigen targets such as CD52, CD30, and CD22 are expressed in various histological subtypes of NHL and are being explored. Despite the promising preliminary phase results further confirmation in the setting of larger clinical trials are needed.


1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: France International Agency for Research on Cancer (IARC); 2008.
2. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res. 2008;14:1550–1560. [PubMed]
3. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998;16:2825–2833. [PubMed]
4. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL. Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459–465. [PubMed]
5. Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol. 2002;13:609–614. [PubMed]
6. Friesen C, Lubatschofski A, Kotzerke J, Buchmann I, Reske SN, Debatin KM. Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging. 2003;30:1251–1261. [PubMed]
7. Zhou L, Yuan R, Serggio L. Molecular mechanisms of irradiation-induced apoptosis. Front Biosci. 2003;8:d9–19. [PMC free article] [PubMed]
8. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 1999;17:3793–3803. [PubMed]
9. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429–4431. [PubMed]
10. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 2002;20:3262–3269. [PubMed]
11. Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, Montini GC, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M. Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk. 2010;10:258–261. [PubMed]
12. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2002;20:2453–2463. [PubMed]
13. Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-Lopez AJ, Witzig TE, White CA. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2003;18:165–178. [PubMed]
14. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol. 2005;23:712–719. [PubMed]
15. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 2001;19:3918–3928. [PubMed]
16. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10:7792–7798. [PubMed]
17. Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J. Clin. Oncol. 2005;23:7985–7993. [PubMed]
18. Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ) Lancet Oncol. 2008;9:352–358. [PubMed]
19. Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, Derenzini E, Rossi M, Pileri S, Fanti S, Baccarani M. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann Oncol. 2012;23:415–420. [PubMed]
20. Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, DeMonaco N, Joyce J, Osborn JL, Evans TL, Schaefer PM, Luong TM. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008;14:7088–7094. [PubMed]
21. Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, Dannaher C, Greco FA. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma. 2009;9:223–228. [PubMed]
22. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 2008;26:5156–5164. [PubMed]
23. Press OW, Unger JM, Rimsza LM, Friedberg J, LeBlanc M, Czuczman MS, Kaminski MS, Braziel RM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 2011;118:98. [PMC free article] [PubMed]
24. Yang DH, Kim WS, Kim SJ, Kim JS, Kwak JY, Chung JS, Oh SY, Suh C, Lee JJ. Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma. 2011 [PubMed]
25. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Bacci F, Pileri S, Baccarani M. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol. 2008;19:769–773. [PubMed]
26. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied N, Hess G, Stein H, Kalmus J, Marcus R. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54–58. [PubMed]
27. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266. [PubMed]
28. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2009;27:5213–5218. [PubMed]
29. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer. 2004;100:2195–2200. [PubMed]
30. Molina A, Krishnan A, Fung H, Flinn IW, Inwards D, Winter JN, Nademanee A. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan. Curr Stem Cell Res Ther. 2007;2:239–248. [PubMed]
31. Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D, Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O'Donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D, Stein A, Spielberger R, Zain J, White C, Raubitschek A. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106:2896–2902. [PubMed]
32. Kang BW, Kim WS, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Invest New Drugs. 2010;28:516–522. [PubMed]
33. Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 2008;26:90–95. [PubMed]
34. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol. 2007;35:534–540. [PubMed]
35. Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF, Appelbaum FR, Press OW. High-dose [131I] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J. Clin. Oncol. 2007;25:1396–1402. [PubMed]
36. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–2942. [PubMed]
37. Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood. 2010;116:1795–1802. [PubMed]
38. Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG, Matesan MC, Storb RF, Press OW. Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood. 2011;118:1132–1139. [PubMed]
39. Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351–2357. [PubMed]
40. Rose Aea. A systematic review and meta-analysis of radioimmunotherapy consolidation for untreated patients with follicular lymphoma. Blood. 2011:118. [PubMed]
41. Gokhale AS, Mayadev J, Pohlman B, Macklis RM. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys. 2005;63:194–201. [PubMed]
42. Press OW, Unger JM, Rimsza LM, Friedberg J, LeBlanc M, Czuczman MS, Kaminski MS, Braziel RM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab vs CHOP Chemotherapy Plus Iodine-131 Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 2011;118:98. [PMC free article] [PubMed]
43. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K, Molina A. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J. Clin. Oncol. 2007;25:4285–4292. [PubMed]
44. Hagenbeek A, Radford J, Van Hoof A, Vitolo U, Rohatiner A, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, Van Putten W, Morschhauser F. 90Y-Ibritumomab Tiuxetan (Zevalin) Consolidation of First remission in Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Followup of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) in 414 Patients. Blood (ASH Annual Meeting Abstracts) 2010;116:594.
45. Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur DS, Stayton PS, Orgun N, Hylarides M, Buchegger F, Kenoyer AL, Axtman A, Gopal AK, Green DJ, Pagel JM, Press OW. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma. Clin Cancer Res. 2011;17:7373–7382. [PMC free article] [PubMed]

Articles from American Journal of Blood Research are provided here courtesy of e-Century Publishing Corporation